ADDISON, Texas, Nov. 12 /PRNewswire-FirstCall/ -- ULURU Inc. , a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced it has entered into definitive agreements to sell 10,714,467 shares of its common stock at a price per share of $0.14 pursuant to a registered direct offering to institutional investors, resulting in gross proceeds of approximately $1.5 million.
The closing of the offering is expected to take place subject to the satisfaction of customary closing conditions. ULURU Inc. plans to use the net proceeds from the offering for research and development and general corporate purposes.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.ULURUinc.com. For further information about Altrazeal(TM), please visit www.Altrazeal.com.
ULURU Inc.
